

# Terzah M Horton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1577849/publications.pdf>

Version: 2024-02-01

81  
papers

1,138  
citations

471509

17  
h-index

414414

32  
g-index

82  
all docs

82  
docs citations

82  
times ranked

1701  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study. <i>Haematologica</i> , 2022, , .	3.5	7
2	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2106-2118.	1.6	45
3	Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, , .	2.5	6
4	Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. <i>Nature Communications</i> , 2022, 13, 2801.	12.8	25
5	Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7504-7504.	1.6	5
6	The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia. <i>Journal of Proteomics</i> , 2021, 233, 104046.	2.4	8
7	Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10018-10018.	1.6	0
8	Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10002-10002.	1.6	0
9	The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6565.	4.1	5
10	Abstract 2349: Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with acute leukemia. , 2021, , .		0
11	Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia. <i>Scientific Reports</i> , 2021, 11, 19613.	3.3	7
12	Gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma. <i>Blood</i> , 2021, , .	1.4	9
13	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-L) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> . 2021. 138. 3487-3487.	1.4	1
14	Valosin-Containing Protein (VCP/p97) Is Prognostically Unfavorable in Subtypes of Acute Leukemia, and Negatively Correlates with UPR-Proteins IRE1 and GRP78. <i>Blood</i> , 2021, 138, 3447-3447.	1.4	0
15	Reverse phase protein arrays in acute leukemia: investigative and methodological challenges. <i>Expert Review of Proteomics</i> , 2021, 18, 1087-1097.	3.0	0
16	Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma. <i>Cancers</i> , 2020, 12, 3603.	3.7	6
17	Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. <i>Haematologica</i> , 2020, 105, 1879-1886.	3.5	83
18	The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	33

#	ARTICLE	IF	CITATIONS
19	Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. <i>Journal of Clinical Investigation</i> , 2020, 130, 863-876.	8.2	36
20	Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231. <i>Blood</i> , 2020, 136, 11-12.	1.4	10
21	Increased Tumor Specific Cytotoxic T Cell Responses and Reversion to a Favorable Cytokine Profile after Treatment in Patients with Newly Diagnosed High Risk Hodgkin Lymphoma Treated on Children's Oncology Group Trial-AHOD1331. <i>Blood</i> , 2020, 136, 41-42.	1.4	1
22	RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. <i>Oncotarget</i> , 2020, 11, 2387-2403.	1.8	18
23	Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor. <i>Blood</i> , 2020, 136, 18-20.	1.4	2
24	Proteomics in Pediatric Acute Myeloid and T-Cell Lymphoblastic Leukemia: Shared Individual Protein Expression Patterns Co-Cluster into Overall Distinct Combinations. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
25	Loss of H3K27 Methylation Identifies Poor Outcome in Adult-Onset Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 24-24.	1.4	2
26	Extracellular vesicles impose quiescence on residual hematopoietic stem cells in the leukemic niche. <i>EMBO Reports</i> , 2019, 20, e47546.	4.5	38
27	Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. <i>British Journal of Haematology</i> , 2019, 186, 274-285.	2.5	65
28	Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. <i>Blood Advances</i> , 2019, 3, 4215-4227.	5.2	34
29	Transmissible ER stress reconfigures the AML bone marrow compartment. <i>Leukemia</i> , 2019, 33, 918-930.	7.2	39
30	Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10033-10033.	1.6	0
31	The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Complex and Supercomplex Formation and Is Necessary for AML Viability. <i>Blood</i> , 2019, 134, 729-729.	1.4	1
32	Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial. <i>Blood</i> , 2019, 134, 2676-2676.	1.4	0
33	Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort. <i>Blood</i> , 2019, 134, 2773-2773.	1.4	0
34	Proteomic Landscape of Acute Leukemia: A Comparison between ALL and AML in Adults. <i>Blood</i> , 2019, 134, 1461-1461.	1.4	0
35	Long-term evidence that a pediatric oncology mentorship program for young investigators is feasible and beneficial in the cooperative group setting: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26878.	1.5	7
36	Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1&2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1229-1238.	10.7	67

#	ARTICLE	IF	CITATIONS
37	Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic. <i>Expert Review of Proteomics</i> , 2018, 15, 613-622.	3.0	3
38	AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow. <i>Blood</i> , 2018, 132, 4034-4034.	1.4	0
39	RPPA-Profilig Identifies Patients with Low Phosphorylation Levels of HSF1 at Serine 326 As Potential Candidate for Bortezomib Treatment in Addition to Standard Therapy in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 293-293.	1.4	4
40	Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 913-913.	1.4	0
41	Signatures of Histone Modification Marks and Proteins in Pediatric Acute Myeloid Leukemia: A Comparison to Adults. <i>Blood</i> , 2018, 132, 2761-2761.	1.4	1
42	The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Supercomplex Formation and Represents a New Therapeutic Target for AML. <i>Blood</i> , 2018, 132, 1335-1335.	1.4	0
43	Proteomic Landscape of De Novo Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 294-294.	1.4	0
44	AXL Expression in Pediatric AML Is Associated with Putative LSC and Correlates with a Distinct Set of Proteins Associated with Cell Metabolism, Cell Cycle, and Unfolded Protein Response. <i>Blood</i> , 2018, 132, 2686-2686.	1.4	0
45	Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1183-1193.	2.0	15
46	Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26487.	1.5	10
47	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2017, 102, e340-e343.	3.5	4
48	Phase 2 trial of brentuximab vedotin and gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma (HL): A Children's Oncology Group (COG) report.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7527-7527.	1.6	5
49	Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 82.	17.0	22
50	A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. <i>Leukemia and Lymphoma</i> , 2016, 57, 1567-1574.	1.3	13
51	Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. <i>Oncotarget</i> , 2016, 7, 74779-74796.	1.8	16
52	Differential Expression of Adhesion Molecule Receptors May Influence Bone Marrow Microenvironment-Mediated Protection of Leukemia-Initiating Cells (LICs) in Infant MLL-rearranged (MLL-R) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016, 128, 1585-1585.	1.4	0
53	Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. <i>Blood</i> , 2016, 128, 4089-4089.	1.4	0
54	Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Suggests New Therapeutic Targets. <i>Blood</i> , 2016, 128, 1712-1712.	1.4	0

#	ARTICLE	IF	CITATIONS
55	JAK/STAT Pathway Inhibition Reverts IL7-Induced Glucocorticoid Resistance in a Subset of Human T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 3963-3963.	1.4	0
56	Yin and yang of glucocorticoid receptors in apoptosis. <i>Blood</i> , 2015, 125, 209-211.	1.4	2
57	A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. <i>British Journal of Haematology</i> , 2015, 170, 118-122.	2.5	22
58	Poorer Relapse-Free Survival in Hispanic Children Diagnosed with Acute Myeloid Leukemia Compared with Non-Hispanics: A Texas Single Institution Experience. <i>Blood</i> , 2015, 126, 1312-1312.	1.4	2
59	Prediction of Primary Treatment Outcome Using Gene Expression Profiling of Pre-Treatment Biopsies Obtained from Childhood and Adolescent Hodgkin Lymphoma Patients. <i>Blood</i> , 2015, 126, 175-175.	1.4	12
60	Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells. <i>Blood</i> , 2015, 126, 3712-3712.	1.4	0
61	A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1754-1760.	1.5	44
62	Protein Expression Clusters Can Differentiate Leukemia Subtypes in Pediatric Leukemia. <i>Blood</i> , 2014, 124, 3784-3784.	1.4	0
63	Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 972-978.	1.5	56
64	Children are not large mice. <i>European Journal of Haematology</i> , 2013, 90, 535-535.	2.2	0
65	Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: A Children's Oncology Group (COG) study (AALL07P1).. <i>Journal of Clinical Oncology</i> , 2013, 31, 10003-10003.	1.6	11
66	Analysis of NF- $\kappa$ B Pathway Proteins in Pediatric Hodgkin Lymphoma: Correlations with EBV Status and Clinical Outcome—A Children's Oncology Group Study. <i>Lymphoma</i> , 2012, 2012, 1-12.	0.2	1
67	A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia: A Children's Oncology Group (COG) Study. <i>Blood</i> , 2012, 120, 3580-3580.	1.4	4
68	AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 3604-3604.	1.4	0
69	Educational paper. <i>European Journal of Pediatrics</i> , 2011, 170, 555-559.	2.7	4
70	Improving T Cell Therapy for Relapsed EBV-Negative Hodgkin's Lymphoma by Targeting Upregulated MAGE-A4. <i>Blood</i> , 2011, 118, 1658-1658.	1.4	0
71	Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference. <i>Pediatric Blood and Cancer</i> , 2010, 54, 872-878.	1.5	22
72	Coordinate Regulation of NF- $\kappa$ B Subunit Expression In Pediatric Hodgkin Lymphoma Patients with Rapid Early Response to Therapy, but Not Slow Early Response to Therapy. <i>Blood</i> , 2010, 116, 2680-2680.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Immune-Based Therapies Targeting Mage-A4 for Relapsed/Refractory Hodgkin's Lymphoma After Stem Cell Transplant.. Blood, 2009, 114, 4089-4089.	1.4	7
74	Heterogeneity in Phenotype, Functional Capacity, and Drug Sensitivity for Pediatric Acute Leukemia.. Blood, 2009, 114, 2654-2654.	1.4	0
75	Coordinate Regulation of NF- $\kappa$ B Subunit Expression in EBV Negative, but Not EBV Positive, Pediatric Hodgkin's Lymphoma. Blood, 2008, 112, 521-521.	1.4	1
76	Targeting the Bcl-2 Family of Proteins in Hodgkin Lymphoma: In Vitro Cytotoxicity, Target Modulation and Drug Combination Studies of the BH3 Mimetic ABT-737. Blood, 2008, 112, 3626-3626.	1.4	1
77	The Cation Transporter SLC22A16 Is Expressed in Pediatric Acute Lymphoblastic Leukemia. Blood, 2008, 112, 4471-4471.	1.4	0
78	A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study. Clinical Cancer Research, 2007, 13, 1516-1522.	7.0	142
79	Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemotherapy and Pharmacology, 2006, 58, 13-23.	2.3	118
80	Case Series of Thrombotic Thrombocytopenic Purpura in Children and Adolescents. Journal of Pediatric Hematology/Oncology, 2003, 25, 336-339.	0.6	32
81	IL-10 and TNF $\alpha$ are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report. Pediatric Hematology and Oncology, 0, , 1-12.	0.8	3